External beam radiotherapy

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Research, NCI, AON, Development, Sarcoma, Disease, Neuroblastoma, Shareholder, Patient, CNS, Fast Track, Cash, SBIR, NDA, Syndrome, Cancer, MRR, CLR, BNS, University, Head, External beam radiotherapy, Cure, Wisconsin Alumni Research Foundation, WAM, HERE, Completeness, Safety, Tat, Intellectual property, Patent, PLE, WARF, Symantec Endpoint Protection, Tranche, UW, Pharmaceutical industry

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.

Presence Receives Fortune 20 Impact Award for World-Changing Innovation in PreK-12 Teletherapy Services

Retrieved on: 
Thursday, February 8, 2024
Mental, Marie Cassidy, School, Student, Growth, Track record, External beam radiotherapy, Mental health, IEP, Individualized Education Program, Person-centered therapy, Nursing

NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Presence, a premier solution for PreK–12 remote evaluation and teletherapy services, has been named to FORTUNE's "Impact 20" list for 2023.

Key Points: 
  • NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Presence, a premier solution for PreK–12 remote evaluation and teletherapy services, has been named to FORTUNE's "Impact 20" list for 2023.
  • The Impact 20 recognizes companies that focus on tackling key social and environmental issues as part of their business models.
  • "Teletherapy expands access to services, and we're proud to have delivered more than 6 million teletherapy sessions through our innovative online platform.
  • It's an honor to be recognized by FORTUNE for our efforts that make a positive impact in the lives of students and clinicians alike."

MySpectrum Counseling & Coaching Ranks #244 on the 2023 Inc. 5000

Retrieved on: 
Tuesday, August 15, 2023
Database, Mental health, Microsoft, Mental, RVA, Chobani, Retail, Nursing, External beam radiotherapy

Number 1 of All Businesses in Richmond, Virginia

Key Points: 
  • Number 1 of All Businesses in Richmond, Virginia
    RICHMOND, Va., Aug. 15, 2023 /PRNewswire-PRWeb/ -- Inc. revealed today that MySpectrum Counseling & Coaching ranks No.
  • 244 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America.
  • MySpectrum Counseling & Coaching is proud to be recognized as number 244 on the 2023 Inc. 5000 List.
  • Mental health is a process, not a destination, and throughout the process, MySpectrum is here – number 244 on the Inc 5000.

ADHD Online to Connect with Patients, Providers and Industry Experts at Annual International ADHD Conference

Retrieved on: 
Monday, November 14, 2022
Online, ADDA, Human, ADHD, Conference, ACO, United States Public Health Service, Internet, Blog, Organization, External beam radiotherapy, Diagnosis, Business development, Annual International Conference on Real Options, Patient, Video game, Medical device

GRAND RAPIDS, Mich., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Teletherapy ADHD diagnosis and treatment company ADHD Online will connect in person with attendees of the 2022 Annual International Conference on ADHD in Dallas, Texas, this week.

Key Points: 
  • GRAND RAPIDS, Mich., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Teletherapy ADHD diagnosis and treatment company ADHD Online will connect in person with attendees of the 2022 Annual International Conference on ADHD in Dallas, Texas, this week.
  • At the conference, ADHD Online will offer fun and impactful learning opportunities for ADHD patients, providers, and professionals with industry leaders and subject matter experts.
  • "We're excited to connect in person with influential members of the ADHD community," said Doug Landman, VP of Business Development.
  • ADHD Online will also host discussions with subject matter experts on ADHD-related topics, including diagnosis, coping mechanisms, and organization for patients and providers.

NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"

Retrieved on: 
Wednesday, October 26, 2022
Innovation, Epilepsy, Company, OTCQB, Disease, Brain, BT, Neurosurgery, Grain, Skull, Laser, Program, NHS, Patient, Technology, Industry, External beam radiotherapy, News, Electron-beam technology, GLOBE, Craniotomy, Seizure, Pain management, United, Pharmaceutical industry, Medical imaging

WAKEFIELD, MA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide shareholders insight on a substantial industry development that is relevant to Innovation Pharmaceuticals’ investment in BT BeaMedical Technologies Ltd. (“BeaMed”).

Key Points: 
  • The implications for introducing laser therapy for epilepsy were summed up by the NHS Medical Director for Specialised Services, characterizing the technology as a game-changing breakthrough.
  • Fiber optic laser therapy offers a monumental improvement in epilepsy care.
  • If approved for epilepsy, BeaMed technology likely would increase the number of candidate patients since it is able to target larger areas of the brain.
  • The Company believes that the NHS news further substantiates its investment in BeaMed and the importance of novel laser therapy approaches, which we expect to become the next standard of care for epilepsy.

EANM Presentations to Showcase New Data and Developments in Telix's Theranostics Pipeline

Retrieved on: 
Monday, October 10, 2022
LinkedIn, Carbonic anhydrase, Congress, Nuclear medicine, Australian Securities Exchange, ASX, Radio, Institute, Regulation of tobacco by the U.S. Food and Drug Administration, Radboud University Medical Center, Patient, PSMA, European Association of Nuclear Medicine, EANM, Research, Cancer, Degenerative disease, Food, TGA, Gallium, Company, Department, Association, Breast cancer, TLX, Prostate cancer, Head, European Association of Urology, Department of Urology, University of Virginia, FDA, Kidney, External beam radiotherapy, Pharmaceutical industry, Medical imaging, Vaccine, Animal, Telix, Urology

Our sponsored symposium provides an insight to the advancements in imaging, surgery and patient management for the genitourinary oncology field.

Key Points: 
  • Our sponsored symposium provides an insight to the advancements in imaging, surgery and patient management for the genitourinary oncology field.
  • The breadth of our innovative theranostic pipeline is demonstrative of our commitment and progress towards advancing nuclear medicine across a range of indications."
  • EANM presentation details are as follows:
    Chairperson: Professor Wolfgang Fendler- Vice Chair, Clinic for Nuclear Medicine, EssenUniversity Hospital, Essen, Germany.
  • -Professor JochenWalz - Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre, Marseille, France.

New Virtual Counseling Practice in Bethesda, MD

Retrieved on: 
Wednesday, September 21, 2022
GA, Counselor, Trauma, List of counseling topics, LPC, Hallmark, Anxiety, Telehealth, Topical steroid withdrawal, Depression, Public relations, External beam radiotherapy

BETHESDA, Md., Sept. 21, 2022 /PRNewswire/ -- Rise Counseling is pleased to announce the opening of their new virtual counseling Practice in Bethesda, Maryland.

Key Points: 
  • BETHESDA, Md., Sept. 21, 2022 /PRNewswire/ -- Rise Counseling is pleased to announce the opening of their new virtual counseling Practice in Bethesda, Maryland.
  • The addition of the new virtual location will allow Rise Counseling Bethesda to bring their therapeutic services to more people in need of support.
  • They offer individual counseling, couples counseling, as well as anxiety therapy.
  • The Rise Counseling Bethesda virtual therapy practice is now hiring therapists and will soon be accepting new clients.

HealthPoint Plus Launches V3.0 of Their Comprehensive Subscription-Based Telehealth Platform

Retrieved on: 
Thursday, March 10, 2022
Safety, ER, English, Mental health, Topical steroid withdrawal, Telehealth, PETS, Prescription, LOI, Multilingualism, MD, OTC Markets Group, Roger Hawkins (drummer), Version 3.0 (album), PCP, Healthpoint, Privacy, Psychology, GLOBE, Calendar, Emotional and behavioral disorders, Solution, United States Secretary of Labor, Pharmacy, Diagnosis, Ampere hour, Urgent care center, Internet, Mobile phone, Health insurance, Medicine, Hospital, External beam radiotherapy

Danvers, Massachusetts, March 10, 2022 (GLOBE NEWSWIRE) -- HealthPoint Plus Inc, a disruptive subscription-based Telehealth medical company who recently signed a LOI to merge with Stargaze Entertainment Group, Inc. (OTC Pink: STGZ), announces the release of HealthPoint Plus Version 3.0, a disruptive Subscription-Based Telehealth Platform.

Key Points: 
  • Danvers, Massachusetts, March 10, 2022 (GLOBE NEWSWIRE) -- HealthPoint Plus Inc, a disruptive subscription-based Telehealth medical company who recently signed a LOI to merge with Stargaze Entertainment Group, Inc. (OTC Pink: STGZ), announces the release of HealthPoint Plus Version 3.0, a disruptive Subscription-Based Telehealth Platform.
  • Telehealth by HealthPoint Plus empowers members and their dependents to video chat with medical doctors or behavioral health providers 24/7/365 to access care from the convenience of their home, office, or anywhere theres an internet connection.
  • Major updates to HealthPoint Plus Version 3.0 include:
    Pet Telehealth - In addition to the existing Urgent Care, Behavioral Health and Virtual Primary Care offerings, HealthPoint Plus will be offering Veterinary Telehealth for pets.
  • This is a great addition to the telehealth suite, and it is being offered alongside traditional telehealth services on a subscription basis.

The Worldwide Radiotherapy Industry is Expected to Reach $6.8 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 18, 2021
Health, Biotechnology, External beam radiotherapy, CAGR, Growth, COVID-19, Pet

Amid the COVID-19 crisis, the global market for Radiotherapy estimated at US$5.6 Billion in the year 2020, is projected to reach a revised size of US$6.8 Billion by 2027, growing at a CAGR of 2.7% over the analysis period 2020-2027.

Key Points: 
  • Amid the COVID-19 crisis, the global market for Radiotherapy estimated at US$5.6 Billion in the year 2020, is projected to reach a revised size of US$6.8 Billion by 2027, growing at a CAGR of 2.7% over the analysis period 2020-2027.
  • External Beam Radiotherapy, one of the segments analyzed in the report, is projected to record a 3.1% CAGR and reach US$3.4 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 5% CAGR
    The Radiotherapy market in the U.S. is estimated at US$1.5 Billion in the year 2020.
  • China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 5.1% over the analysis period 2020 to 2027.

Chile Radiotherapy Market Size, Share & Trends Analysis 2021-2028 by Type (External Beam, Internal Beam, Systemic Radiotherapy), Application (Breast, Prostate, Lung, Colorectal, Head & Neck Cancer) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 1, 2021
Radiology, Health, Necrosis, Lymphedema, CAGR, Growth, Smoking, External beam radiotherapy, Incidence, Fluid mechanics, Acquisition, Lung, Radiation, Lung cancer, Particle accelerator, EBRT, Prevalence, Death, Cobalt therapy, Canadian International Council, Prostate, Organic, Apoptosis, Prostate cancer, International Agency for Research on Cancer, USD, Radiation therapy, IARC, Medical imaging, Lithium

The "Chile Radiotherapy Market Size, Share & Trends Analysis Report by Type (External Beam, Internal Beam, Systemic Radiotherapy), by Application (Breast, Prostate, Lung, Colorectal, Head & Neck Cancer), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chile Radiotherapy Market Size, Share & Trends Analysis Report by Type (External Beam, Internal Beam, Systemic Radiotherapy), by Application (Breast, Prostate, Lung, Colorectal, Head & Neck Cancer), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Chile radiotherapy market size is expected to reach USD 36.0 million by 2028.
  • The increasing prevalence of cancer and rising healthcare expenditure are factors expected to propel the growth over the forecast period.
  • There is a significant gap between the required and installed radiotherapy capacity in Chile.